Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4
Brief Summary: GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and ribavirin in subjects with chronic hepatitis C (CHC).


Options:
A: Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks
B: Arm Label: LDV/SOF 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 12 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 Week, LDV/SOF 8 Week, LDV/SOF+RBV 8 Week | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 8 Week
C: Arm Label: GSK2336805; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK2336805 Matching Placebo | Arm Label: GSK2336805 + pegylated interferon alfa-2a + ribavrin; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: Placebo + pegylated interferon alfa-2a + ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alfa-2a, Drug: Ribavirin, Drug: GSK2336805 Matching Placebo | Intervention Type: DRUG; Name: GSK2336805; Assigned to Arm(s): GSK2336805, GSK2336805 + pegylated interferon alfa-2a + ribavrin | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): GSK2336805 + pegylated interferon alfa-2a + ribavrin, Placebo + pegylated interferon alfa-2a + ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): GSK2336805 + pegylated interferon alfa-2a + ribavrin, Placebo + pegylated interferon alfa-2a + ribavirin | Intervention Type: DRUG; Name: GSK2336805 Matching Placebo; Assigned to Arm(s): Placebo, Placebo + pegylated interferon alfa-2a + ribavirin
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: C